

**RHEUMATOLOGY REFERRAL FORM**

Non-Infusion Drug Names Starting with A - H  
 Prescriber, please sign and fax completed form to 713.704.3841  
 For questions, please call 281.698.6100

SHIP TO:  Patient  
 Office (1st dose)  
 Office (All doses)

**Patient Information** \*\*Please include copy of prescription and medical insurance card, front and back\*\*

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
 Street Address: \_\_\_\_\_ Phone: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_ Allergies: \_\_\_\_\_

**Prescriber Information**

Prescriber Name: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Specialty: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Office Street Address: \_\_\_\_\_ Fax: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_ Office Contact: \_\_\_\_\_

**Patient Medical Information** \*\*Please include copies of any pertinent clinical notes and lab work \*\*

Diagnosis (ICD-10):  M06.9 (Rheumatoid Arthritis)  L40.59 (Psoriatic Arthritis)  M45.9 (Ankylosing Spondylitis)  
 M08.0 (Juvenile Idiopathic Arthritis)  L40.54 (Psoriatic Juvenile Arthritis)  Other \_\_\_\_\_  
 Diagnosis Date: \_\_\_\_\_ Date of negative TB Test: \_\_\_\_\_ Date of negative chest X-ray (if TB positive): \_\_\_\_\_

**Previous and/or Current Medications Used to Treat this Diagnosis:**

Medication Name(s)	Current Use	Start Date	End Date	Discontinue Reason (if stopped)
	<input type="checkbox"/>			<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
	<input type="checkbox"/>			<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
	<input type="checkbox"/>			<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____

**Prescription Information**

		Quantity	Form	Refills
<input type="checkbox"/> Actemra (tocilizumab)	<input type="checkbox"/> Inject 162 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 162 mg subcutaneously weekly	<input type="checkbox"/> #2 (162 mg / 0.9 mL) <input type="checkbox"/> #4 (162 mg / 0.9 mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	Refills: ____
<input type="checkbox"/> Amjevita (adalimumab-atto)	<b>Adult</b> <input type="checkbox"/> Inject 40 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 40 mg subcutaneously weekly <input type="checkbox"/> Inject 80 mg subcutaneously every 2 weeks	<input type="checkbox"/> #2 (40 mg / 0.8 mL) <input type="checkbox"/> #4 (40 mg / 0.8 mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	Refills: ____
	<b>Pediatric</b> <input type="checkbox"/> Inject 20 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 40 mg subcutaneously every 2 weeks	<input type="checkbox"/> #2 (20 mg / 0.4 mL) <input type="checkbox"/> #2 (40 mg / 0.8 mL)	<input type="checkbox"/> Auto Injector (40 mg only) <input type="checkbox"/> PFS	
<input type="checkbox"/> Cimzia (certolizumab)	<b>Initial (if applicable)</b> <input type="checkbox"/> Inject 400 mg subcutaneously at weeks 0, 2, and 4	<input type="checkbox"/> #6 (200 mg / mL)	PFS	No Refills
	<b>Maintenance (Starting [ ] weeks after initial dose, if applicable)</b> <input type="checkbox"/> Inject 200 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 400 mg subcutaneously every 4 weeks	<input type="checkbox"/> #2 (200 mg / mL)	PFS	Refills: ____
<input type="checkbox"/> Cosentyx (secukinumab)	<b>Initial (if applicable)</b> <input type="checkbox"/> Inject 150 mg subcutaneously at weeks 0, 1, 2, 3 <input type="checkbox"/> Inject 300 mg subcutaneously at weeks 0, 1, 2, 3	<input type="checkbox"/> #4 (150 mg / mL) <input type="checkbox"/> #8 (150 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	No Refills
	<b>Maintenance (Starting on week 4 after initial dose, if applicable)</b> <input type="checkbox"/> Inject 150 mg subcutaneously every 4 weeks <input type="checkbox"/> Inject 300 mg subcutaneously every 4 weeks	<input type="checkbox"/> #1 (150 mg / mL) <input type="checkbox"/> #2 (150 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	Refills: ____
<input type="checkbox"/> Enbrel (etanercept)	<input type="checkbox"/> Inject 50 mg subcutaneously weekly <input type="checkbox"/> Inject 25 mg subcutaneously two times per week <input type="checkbox"/> Inject 50 mg subcutaneously two times per week <input type="checkbox"/> Inject ____ mg (0.8 mg / kg x ____ weight in kg) subQ weekly	<input type="checkbox"/> #4 (50 mg / mL) <input type="checkbox"/> #____ (25 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> Mini Cartridge <input type="checkbox"/> PFS <input type="checkbox"/> Vial	Refills: ____
<input type="checkbox"/> Humira (adalimumab)	<b>Adult</b> <input type="checkbox"/> Inject 40 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 40 mg subcutaneously weekly	<input type="checkbox"/> #2 (40 mg / 0.4 mL) <input type="checkbox"/> #4 (40 mg / 0.4 mL)	<input type="checkbox"/> Pen <input type="checkbox"/> PFS	Refills: ____
	<b>Pediatric</b> <input type="checkbox"/> Inject 10 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 20 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 40 mg subcutaneously every 2 weeks	<input type="checkbox"/> #2 (10 mg / 0.1 mL) <input type="checkbox"/> #2 (20 mg / 0.2 mL) <input type="checkbox"/> #2 (40 mg / 0.4 mL)	<input type="checkbox"/> Pen (40 mg only) <input type="checkbox"/> PFS (all doses)	Refills: ____

**Prescriber Signature (No Stamps Permitted)**

By signing below, I authorize Memorial Hermann Specialty Pharmacy to serve as my designated agent, if needed, to initiate and execute any applicable authorization processes with medical and prescription insurance companies. To prohibit generic substitution write "brand necessary" or "brand medically necessary" on the face of the referral form in your own handwriting.

Prescriber's Signature : \_\_\_\_\_ Date: \_\_\_\_\_

Confidentiality Notice - Warning: Unauthorized interception of this fax communication could be a violation of federal and state law. The documents accompanying this fax transmission may contain information that is legally privileged. The information is intended only for use by the recipient. You are hereby notified that any disclosure, copying, distribution, or taking of any action on the contents of this faxed information is strictly prohibited. If you have received this information in error, please immediately notify sender by telephone to arrange for the return of the original documents.

**RHEUMATOLOGY REFERRAL FORM**

Non-Infusion Drug Names Starting with K – S  
 Prescriber, please sign and fax completed form to 713.704.3841  
 For questions, please call 281.698.6100

SHIP TO:  Patient  
 Office (1st dose)  
 Office (All doses)

**Patient Information** **\*\*Please include copy of prescription and medical insurance card, front and back\*\***

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
 Street Address: \_\_\_\_\_ Phone: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_ Allergies: \_\_\_\_\_

**Prescriber Information**

Prescriber Name: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Specialty: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Office Street Address: \_\_\_\_\_ Fax: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_ Office Contact: \_\_\_\_\_

**Patient Medical Information** **\*\*Please include copies of any pertinent clinical notes and lab work \*\***

Diagnosis (ICD-10):  M06.9 (Rheumatoid Arthritis)  L40.59 (Psoriatic Arthritis)  M45.9 (Ankylosing Spondylitis)  
 M08.0 (Juvenile Idiopathic Arthritis)  L40.54 (Psoriatic Juvenile Arthritis)  Other \_\_\_\_\_  
 Diagnosis Date: \_\_\_\_\_ Date of negative TB Test: \_\_\_\_\_ Date of negative chest X-ray (if TB positive): \_\_\_\_\_

**Previous and/or Current Medications Used to Treat this Diagnosis:**

Medication Name(s)	Current Use	Start Date	End Date	Discontinue Reason (if stopped)
_____	<input type="checkbox"/>	_____	_____	<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
_____	<input type="checkbox"/>	_____	_____	<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
_____	<input type="checkbox"/>	_____	_____	<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____

**Prescription Information**

	Quantity	Form	Refills
<input type="checkbox"/> <b>Kevzara</b> (sarilumab) <input type="checkbox"/> Inject 150 mg subcutaneously every 2 weeks <input type="checkbox"/> Inject 200 mg subcutaneously every 2 weeks	<input type="checkbox"/> #2 (150 mg / 1.14 mL) <input type="checkbox"/> #2 (200 mg / 1.14 mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	Refills: ____
<input type="checkbox"/> <b>Methotrexate</b> <input type="checkbox"/> Take ____ tablets by mouth ____ times weekly <input type="checkbox"/> Inject ____ mg subcutaneously weekly	<input type="checkbox"/> # ____ (____ mg tablet) <input type="checkbox"/> #4 (____ mg / ____ mL)	<input type="checkbox"/> Tablet <input type="checkbox"/> Otrexup Injector <input type="checkbox"/> Rasuvo Injector <input type="checkbox"/> RediTrex Injector	Refills: ____
<input type="checkbox"/> <b>Olumiant</b> (baricitinib) <input type="checkbox"/> Take 1 tablet by mouth daily	<input type="checkbox"/> #30 (2 mg tablet)	Tablet	Refills: ____
<input type="checkbox"/> <b>Orencia</b> (abatacept) <input type="checkbox"/> Inject 125 mg subcutaneously weekly	<input type="checkbox"/> #4 (125 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	Refills: ____
<input type="checkbox"/> <b>Otezla</b> (apremilast) <u>Initial (if applicable)</u> <input type="checkbox"/> Take as directed on the package instructions	<input type="checkbox"/> #55 (28-day starter)	Tablet	No Refills
	<u>Maintenance</u> <input type="checkbox"/> Take 1 tablet by mouth twice daily	<input type="checkbox"/> #60 (30 mg tablet)	Tablet
<input type="checkbox"/> <b>Prednisone</b> <input type="checkbox"/> Take ____ tablets by mouth ____ times daily	<input type="checkbox"/> # ____ (____ mg tablet)	Tablet	Refills: ____
<input type="checkbox"/> <b>Rinvoq</b> (baricitinib) <input type="checkbox"/> Take 1 tablet by mouth daily	<input type="checkbox"/> #30 (15 mg tablet)	Tablet	Refills: ____
<input type="checkbox"/> <b>Simponi</b> (golimumab) <input type="checkbox"/> Inject 50 mg subcutaneously once a month	<input type="checkbox"/> #1 (50 mg / 0.5 mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	Refills: ____
<input type="checkbox"/> <b>Skyrizi</b> (risankizumab) <u>Initial (if applicable)</u> <input type="checkbox"/> Inject 150 mg subcutaneously once	<input type="checkbox"/> #1 (150 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	No Refills
	<u>Maintenance (Starting 4 weeks after initial dose, if applicable)</u> <input type="checkbox"/> Inject 150 mg subcutaneously every 12 weeks	<input type="checkbox"/> #1 (150 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS
<input type="checkbox"/> <b>Stelara</b> (ustekinumab) <u>Initial (if applicable)</u> <input type="checkbox"/> Inject 45 mg subcutaneously once <input type="checkbox"/> Inject 90 mg subcutaneously once	<input type="checkbox"/> #1 (45 mg / 0.5 mL) <input type="checkbox"/> #1 (90 mg / mL)	<input type="checkbox"/> PFS	No Refills
	<u>Maintenance (Starting 4 weeks after initial dose, if applicable)</u> <input type="checkbox"/> Inject 45 mg subcutaneously every 12 weeks <input type="checkbox"/> Inject 90 mg subcutaneously every 12 weeks	<input type="checkbox"/> #1 (45 mg / 0.5 mL) <input type="checkbox"/> #1 (90 mg / mL)	<input type="checkbox"/> PFS

**Prescriber Signature (No Stamps Permitted)**

By signing below, I authorize Memorial Hermann Specialty Pharmacy to serve as my designated agent, if needed, to initiate and execute any applicable authorization processes with medical and prescription insurance companies. To prohibit generic substitution write "brand necessary" or "brand medically necessary" on the face of the referral form in your own handwriting.

Prescriber's Signature : \_\_\_\_\_ Date: \_\_\_\_\_

Confidentiality Notice - Warning: Unauthorized interception of this fax communication could be a violation of federal and state law. The documents accompanying this fax transmission may contain information that is legally privileged. The information is intended only for use by the recipient. You are hereby notified that any disclosure, copying, distribution, or taking of any action on the contents of this faxed information is strictly prohibited. If you have received this information in error, please immediately notify sender by telephone to arrange for the return of the original documents.

**RHEUMATOLOGY REFERRAL FORM**

Non-Infusion Drug Names Starting with T - Z  
 Prescriber, please sign and fax completed form to 713.704.3841  
 For questions, please call 281.698.6100

SHIP TO:  Patient  
 Office (1st dose)  
 Office (All doses)

**Patient Information** \*\*Please include copy of prescription and medical insurance card, front and back\*\*

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
 Street Address: \_\_\_\_\_ Phone: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_ Allergies: \_\_\_\_\_

**Prescriber Information**

Prescriber Name: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Specialty: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Office Street Address: \_\_\_\_\_ Fax: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_ Office Contact: \_\_\_\_\_

**Patient Medical Information** \*\*Please include copies of any pertinent clinical notes and lab work \*\*

Diagnosis (ICD-10):  M06.9 (Rheumatoid Arthritis)  L40.59 (Psoriatic Arthritis)  M45.9 (Ankylosing Spondylitis)  
 M08.0 (Juvenile Idiopathic Arthritis)  L40.54 (Psoriatic Juvenile Arthritis)  Other \_\_\_\_\_  
 Diagnosis Date: \_\_SSS\_\_\_\_\_ Date of negative TB Test: \_\_\_\_\_ Date of negative chest X-ray (if TB positive): \_\_\_\_\_

**Previous and/or Current Medications Used to Treat this Diagnosis:**

Medication Name(s)	Current Use	Start Date	End Date	Discontinue Reason (if stopped)
_____	<input type="checkbox"/>	_____	_____	<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
_____	<input type="checkbox"/>	_____	_____	<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
_____	<input type="checkbox"/>	_____	_____	<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____

**Prescription Information**

		Quantity	Form	Refills
<input type="checkbox"/> Taltz (ixekizumab)	Initial (if applicable) <input type="checkbox"/> Inject 160 mg (2 x 80 mg) subcutaneously once	<input type="checkbox"/> #2 (80 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	No Refills
	Maintenance (Starting 4 weeks after initial dose, if applicable) <input type="checkbox"/> Inject 80 mg subcutaneously every 4 weeks	<input type="checkbox"/> #1 (80 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	Refills: ____
<input type="checkbox"/> Tremfya (guselkumab)	Initial (if applicable) <input type="checkbox"/> Inject 100 mg subcutaneously once	<input type="checkbox"/> #1 (100 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	No Refills
	Maintenance (Starting 4 weeks after initial dose, if applicable) <input type="checkbox"/> Inject 100 mg subcutaneously every 8 weeks	<input type="checkbox"/> #1 (100 mg / mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	Refills: ____
<input type="checkbox"/> Xeljanz (tofacitinib)	<input type="checkbox"/> Take 1 tablet by mouth twice daily	<input type="checkbox"/> #60 (5 mg tablet)	Tablet	Refills: ____
<input type="checkbox"/> Xeljanz XR (tofacitinib)	<input type="checkbox"/> Take 1 tablet by mouth daily	<input type="checkbox"/> #30 (11 mg tablet)	Tablet	Refills: ____
<input type="checkbox"/> Xeljanz - oral solution (tofacitinib)	<input type="checkbox"/> Take 3.2 mg by mouth twice daily <input type="checkbox"/> Take 4 mg by mouth twice daily <input type="checkbox"/> Take 5 mg by mouth twice daily	<input type="checkbox"/> #1 (1 mg / mL)	240 mL bottle	Refills: ____
<input type="checkbox"/> Other:		# _____		Refills: ____

**Prescriber Signature (No Stamps Permitted)**

By signing below, I authorize Memorial Hermann Specialty Pharmacy to serve as my designated agent, if needed, to initiate and execute any applicable authorization processes with medical and prescription insurance companies. To prohibit generic substitution write "brand necessary" or "brand medically necessary" on the face of the referral form in your own handwriting.

Prescriber's Signature : \_\_\_\_\_ Date: \_\_\_\_\_

Confidentiality Notice - Warning: Unauthorized interception of this fax communication could be a violation of federal and state law. The documents accompanying this fax transmission may contain information that is legally privileged. The information is intended only for use by the recipient. You are hereby notified that any disclosure, copying, distribution, or taking of any action on the contents of this faxed information is strictly prohibited. If you have received this information in error, please immediately notify sender by telephone to arrange for the return of the original documents.